所有图片(1)
别名:
β-二甲基氨基乙基-2-甲基二苯甲醚 盐酸盐, N,N-二甲基-2-(2-甲基二苯甲基氧基)乙胺 盐酸盐, 邻甲苯海明 盐酸盐
经验公式（希尔记法）:
C18H23NO · HCl
CAS号:
分子量:
305.84
Beilstein:
3745818
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
推荐产品
![2-[(2-Amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy]ethyl N-(benzyloxycarbonyl)-L-valinate pharmaceutical impurity standard](/deepweb/assets/sigmaaldrich/product/structures/160/429/6e72e657-3546-405b-90a0-4160b455c749/640/6e72e657-3546-405b-90a0-4160b455c749.png)
等级
pharmaceutical primary standard
API类
orphenadrine
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
格式
neat
储存温度
2-8°C
SMILES字符串
Cl.CN(C)CCOC(c1ccccc1)c2ccccc2C
InChI
1S/C18H23NO.ClH/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16;/h4-12,18H,13-14H2,1-3H3;1H
InChI key
UQZKYYIKWZOKKD-UHFFFAOYSA-N
基因信息
human ... GRIN1(2902) , GRIN2A(2903) , GRIN2B(2904) , GRIN2C(2905) , GRIN2D(2906) , GRIN3A(116443) , GRIN3B(116444) , HRH1(3269) , SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335) , SLC6A2(6530)
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Orphenadrine hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化/生理作用
毒蕈碱型受体拮抗剂；H1 组胺受体拮抗剂；肌肉松弛剂。据报道，奥芬那君还可抑制去甲肾上素转运蛋白并且阻塞 NMDA 受体离子通道。
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
相关产品
产品编号
说明
价格
警示用语：
Danger
危险声明
危险分类
Acute Tox. 3 Oral
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Jean-François Desaphy et al.
Experimental neurology, 255, 96-102 (2014-03-13)
Although the sodium channel blocker mexiletine is considered the first-line drug in myotonia, some patients experiment adverse effects, while others do not gain any benefit. Other antimyotonic drugs are thus needed to offer mexiletine alternatives. In the present study, we
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门